Søren Neve

Søren Neve has had a successful career in the pharmaceutical industry, beginning in 2002 as a Senior Scientist at Nuevolution A/S. In 2006, they became a Project Lead at Novozymes, and then in 2011, they were appointed as COO of Adenium Biotech ApS. In 2015, they became Founder of Defensin Therapeutics and Director of Drug Discovery and Pharmacology at Orphazyme A/S. Most recently, in 2022, they were appointed as Head of Pharmacology at Synklino.

Søren Neve obtained a Doctor of Philosophy (PhD) in Molecular Biology from Syddansk Universitet - University of Southern Denmark between 1986 and 1998.